Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Allergan.

Clinical Briefings™: Advances in Anti-VEGF Therapies for Neovascular Age-Related Macular Degeneration

Release Date: June 30, 2020
Expiration Date: June 30, 2021

Activity Overview

This online activity is designed to provide a concise and focused overview on the complex pathophysiology and etiology of neovascular age-related macular degeneration (nAMD), the clinical presentation and diagnostic evaluation of nAMD, and the efficacy and safety of currently approved and investigational therapies for treating this common cause of blindness. The engaging, multimedia format of this program includes audio commentary from an expert thought leader integrated with text-based elements.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Allergan.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This online educational activity is directed toward ophthalmologists and other health care professionals involved in the treatment of nAMD.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Address best practices for screening, diagnosis, and monitoring of patients with AMD
  • Evaluate the efficacy and safety data for therapies targeting AMD
  • Assess barriers to optimal management of patients with AMD (eg, nonadherence, noncompliance, treatment intolerance), and devise strategies to address these needs

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Andrew A. Moshfeghi, MD, MBA
Andrew A. Moshfeghi, MD, MBA
Associate Professor of Clinical Ophthalmology
Director: Vitreoretinal Surgery Fellowship
Director: Clinical Trials Unit
USC Roski Eye Institute, RETINA SERVICE
Keck School of Medicine
University of Southern California
Los Angeles, CA

Disclosures: Grant/Research Support: Allegro, Genentech, Regeneron, Novartis. Consultant: Novartis, Genentech, Regeneron, Allegro, Graybug, Clearside, Allergan, Alimera, Pr3vent. Speaker's Bureau: Allergan. Stock/ Shareholder: Pr3vent, OptiSTENT.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By